SSPL WEALTH PVT LTD

Hot Pursuit

Scrips, which has significant changes during the market hours.

Biocon Q4 PAT zooms 154% YoY to Rs 344 crore

09-May-25 11:05 Hrs IST

Revenue from operations increased 12.76% YoY to Rs 4,417 crore during the period under review.

Profit before tax in Q4 FY25 stood at Rs 487 crore, up 53% from Rs 319 crore in Q4 FY24.

EBITDA increased by 15% to Rs 1,115 crore in Q4 FY25 from Rs 964 crore in Q4 FY24.

The company's generics business jumped 45.81% year on year to Rs 718.40 in Q4 FY25, driven largely by the sale of launch quantities of Lenalidomide capsules in the U.S., following a settlement with the innovator company.

A growth was also supplemented by the UK launch of Biocon's first GLP-1 product, Liraglutide, under the brand names, Liraglutide Biocon to treat diabetes and Biolide for chronic weight management. A distribution partnership for Liraglutide executed for retail markets in the UK and the Netherlands will enable the Company to expand the product's reach in the region.

Biocon Biologics, which houses Biocon's biosimilars business, has reported 8% rise up in revenue to Rs 2,463 crore.

Syngene, which is the Research services division of Biocon, has registered 11% increase in revenue to Rs 1,018 crore in the fourth quarter as compared with the same period last year.

The company's Research & Development expenses were at Rs 231 crore in Q4 FY25, down 6% YoY.

Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said, 'The Biocon Group ended the year with a strong performance across its businesses. The launch of Liraglutide in the UK market heralded our entry into the GLP-1 therapy segment. Our Biosimilars continue to build impressive shares in global markets with four biosimilars recording sales of USD 200 million each in FY25.

We also launched our fifth biosimilar product Yesintek' (bUstekinumab) in the U.S. market. This quarter marked the expansion of Syngene's biologics manufacturing footprint through an acquisition of a state-of-the-art manufacturing facility in the U.S. FY25 has been a year of consolidation and transition. We are now on a path of accelerating growth with a commitment to innovation, digital augmentation and operational excellence.'

Meanwhile, the board of directors has recommended a final dividend of Rs 0.50 per share at the rate of 10% of the face value of the share, for the financial year ended 31 March 2025.

Further, Peter Bains has been appointed as a full-time CEO & Managing Director at Syngene International, and has hence stepped down from the role of Group CEO of Biocon w.e.f. 1 April 2025.

Lastly, the company said its board has approved raising of funds up to Rs 4,500 crore, through the issue of securities. Besides, the Board constitutes a committee to evaluate various strategic options for restructuring including the merger of Biocon Biologics and Biocon. Such options shall be evaluated taking into consideration matters relating to legal and tax aspects, and subject to receipt of all approvals, including approval of the Board and the shareholders of the Company and other regulatory/statutory approvals, it added.

Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

Shares of Biocon fell 1.55% to Rs 329.40 on the BSE.